{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:37:13Z","timestamp":1790617033118,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,10,11]],"date-time":"2010-10-11T00:00:00Z","timestamp":1286755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,10,11]],"date-time":"2010-10-11T00:00:00Z","timestamp":1286755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1038\/bmt.2010.225","type":"journal-article","created":{"date-parts":[[2010,10,11]],"date-time":"2010-10-11T10:48:24Z","timestamp":1286794104000},"page":"962-969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment"],"prefix":"10.1038","volume":"46","author":[{"given":"M","family":"Shafey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Lupichuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D A","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,11]]},"reference":[{"key":"BFbmt2010225_CR1","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"JO Armitage","year":"1998","unstructured":"Armitage JO, Weisenburger DD . New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol 1998; 16: 2780\u20132795.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010225_CR2","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","volume":"15","author":"Y Bastion","year":"1997","unstructured":"Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontel C et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15: 1587\u20131594.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010225_CR3","first-page":"75","volume":"20","author":"SJ Horning","year":"1993","unstructured":"Horning SJ . Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75\u201388.","journal-title":"Semin Oncol"},{"key":"BFbmt2010225_CR4","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","volume":"311","author":"SJ Horning","year":"1984","unstructured":"Horning SJ, Rosenberg SA . The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471\u20131475.","journal-title":"N Engl J Med"},{"key":"BFbmt2010225_CR5","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH van Oers","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne R et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295\u20133301.","journal-title":"Blood"},{"key":"BFbmt2010225_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1023\/A:1008381105849","volume":"11","author":"CR Crawley","year":"2000","unstructured":"Crawley CR, Foran JM, Gupta RK, Rohatnier AZS, Summers K, Matthews J et al. A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann Oncol 2000; 11: 861\u2013865.","journal-title":"Ann Oncol"},{"key":"BFbmt2010225_CR7","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064\u20133071.","journal-title":"Blood"},{"key":"BFbmt2010225_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1365-2354.1997.tb00321.x","volume":"6","author":"MJ Keating","year":"1997","unstructured":"Keating MJ, McLaughlin P, Cabanillas F . Low-grade non-Hodgkin's lymphoma\u2013development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND). Eur J Cancer Care (Engl) 1997; 6: 21\u201326.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"BFbmt2010225_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/10428190500376076","volume":"47","author":"C Emmanouilides","year":"2006","unstructured":"Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 629\u2013636.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2010225_CR10","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","volume":"103","author":"LI Gordon","year":"2004","unstructured":"Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study. Blood 2004; 103: 4429\u20134431.","journal-title":"Blood"},{"key":"BFbmt2010225_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/cbr.2005.20.185","volume":"20","author":"GA Wiseman","year":"2005","unstructured":"Wiseman GA, Witzig TE . Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005; 20: 185\u2013188.","journal-title":"Cancer Biother Radiopharm"},{"key":"BFbmt2010225_CR12","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453\u20132463.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010225_CR13","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","volume":"25","author":"AZ Rohatiner","year":"2007","unstructured":"Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007; 25: 2554\u20132559.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010225_CR14","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hogberg H, Johnsen HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918\u20133927.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010225_CR15","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","volume":"102","author":"K van Besien","year":"2003","unstructured":"van Besien K, Loberiza Jr FR, Bajorunaite R, Armitage JO, Bashey A, Burns L et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521\u20133529.","journal-title":"Blood"},{"key":"BFbmt2010225_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/bmj.328.7436.360","volume":"328","author":"M Ryan","year":"2004","unstructured":"Ryan M . Discrete choice experiments in health care. BMJ 2004; 328: 360\u2013361.","journal-title":"BMJ"},{"key":"BFbmt2010225_CR17","first-page":"55","volume":"2","author":"M Ryan","year":"2003","unstructured":"Ryan M, Gerard K . Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy 2003; 2: 55\u201364.","journal-title":"Appl Health Econ Health Policy"},{"key":"BFbmt2010225_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta5050","volume":"5","author":"M Ryan","year":"2001","unstructured":"Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM et al. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess 2001; 5: 1\u2013186.","journal-title":"Health Technol Assess"},{"key":"BFbmt2010225_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J . Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics 2008; 26: 661\u2013677.","journal-title":"Pharmacoeconomics"},{"key":"BFbmt2010225_CR20","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511610356","volume-title":"Applied Choice Analysis: a Primer","author":"DA Hensher","year":"2005","unstructured":"Hensher DA, Rose JM, Greene WH . Applied Choice Analysis: a Primer. Cambridge University Press: Cambridge, 2005."},{"key":"BFbmt2010225_CR21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/hec.1104","volume":"15","author":"E Lancsar","year":"2006","unstructured":"Lancsar E, Louviere J . Deleting \u2018irrational\u2019 responses from discrete choice experiments: a case of investigating or imposing preferences? Health Econ 2006; 15: 797\u2013811.","journal-title":"Health Econ"},{"key":"BFbmt2010225_CR22","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.ejca.2007.04.021","volume":"43","author":"LJ Caldon","year":"2007","unstructured":"Caldon LJ, Walters SJ, Ratcliffe J, Reed MW . What influences clinicians\u2019 operative preferences for women with breast cancer? An application of the discrete choice experiment. Eur J Cancer 2007; 43: 1662\u20131669.","journal-title":"Eur J Cancer"},{"key":"BFbmt2010225_CR23","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/bjs.4917","volume":"92","author":"G Salkeld","year":"2005","unstructured":"Salkeld G, Solomon M, Butow P, Short L . Discrete-choice experiment to measure patient preferences for the surgical management of colorectal cancer. Br J Surg 2005; 92: 742\u2013747.","journal-title":"Br J Surg"},{"key":"BFbmt2010225_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/bmj.37972.497234.44","volume":"328","author":"M Sculpher","year":"2004","unstructured":"Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M . Patients\u2019 preferences for the management of non-metastatic prostate cancer: discrete choice experiment. BMJ 2004; 328: 382.","journal-title":"BMJ"},{"key":"BFbmt2010225_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/hec.720","volume":"11","author":"J Cairns","year":"2002","unstructured":"Cairns J, van der Pol M, Lloyd AJ . Decision making heuristics and the elicitation of preferences: being fast and frugal about the future. Health Econ 2002; 11: 655\u2013658.","journal-title":"Health Econ"},{"key":"BFbmt2010225_CR26","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.bbmt.2007.04.009","volume":"13","author":"M Sabloff","year":"2007","unstructured":"Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007; 13: 956\u2013964.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010225_CR27","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","volume":"21","author":"S Montoto","year":"2007","unstructured":"Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007; 21: 2324\u20132331.","journal-title":"Leukemia"},{"key":"BFbmt2010225_CR28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood.V114.22.363.363","volume":"114","author":"C Tarella","year":"2009","unstructured":"Tarella C, Ladetto M, Benedetti F, Vitolo U, Pulsoni A, Patti C et al. A recent update of three consecutive prospective trials with high-dose therapy and autograft, without or with rituximab, as primary treatment for advanced-stage follicular lymphoma (FL) shows a sizeable group of patients surviving in continuous complete remission up to 16 years after the end of treatment: should we still consider FL an incurable disease? Blood 2009; 114: 363 (abstract 882).","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2010225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2010225","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2010225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T13:28:11Z","timestamp":1648042091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2010225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,11]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["BFbmt2010225"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2010.225","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,11]]},"assertion":[{"value":"6 April 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}